Physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey

Stoll, Marlene; Hubenschmid, Lara; Koch, Cora; Lieb, Klaus; Egloff, Boris

doi:10.1136/bmjopen-2021-055963

Cited by 4 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is considerable evidence that this COI often favors companies ( 3 ). Some studies show considerable concern about these interactions, especially in financial interest cases, as such links potentially lead to systematic biases in patient care ( 4 ). Physicians are the gatekeepers determining how money is spent in the health system.…”

Section: Introductionmentioning

confidence: 99%

Interaction between physicians and the pharmaceutical industry: A scoping review for developing a policy brief

Zarei

Ghaffari

Nikoobar

et al. 2023

Front. Public Health

View full text Add to dashboard Cite

BackgroundPayments to physicians by the pharmaceutical industry are common, but recent evidence shows that these payments influence physician prescribing behavior in the form of increased prescription of brand-name drugs, expensive and low-cost drugs, increased prescription of payer company drugs, etc. Considering that these payments increase drug costs for patients and health systems, there is a public interest in controlling them. Therefore, this study aimed to identify and propose policy options for managing physician-pharmaceutical industry interactions in the context of Iran's health system.MethodsIn the first phase, a systematic search was conducted to identify relevant policies and interventions in Web of Science, PubMed, and ProQuest databases from 2000 to 2022. Then, the opinions of the research team and an expert group (physicians, health policy and transparency experts, and industry representatives) were used to categorize the interventions and propose policy options along with their advantages, disadvantages, and implementation considerations.ResultsIn the search, 579 articles were retrieved, and 44 articles were found suitable for the final analysis. Twenty-nine interventions and strategies were identified, and based on these; Five policy options were identified: prohibition, restriction, physician self-regulation, voluntary industry disclosure, and mandatory industry disclosure.ConclusionThe proposed policies in our study include advantages, challenges, and implementation considerations based on up-to-date evidence that can help policymakers use them to manage COI in physician-pharmaceutical industry interactions in Iran's health system. A combination of measures seems to help manage COI: firstly, using self-regulating physicians and industry to institutionalize transparency, and in the next step, implementing mandatory industry disclosure policies and establishing restrictions on some financial interactions.

show abstract

Section: Introductionmentioning

confidence: 99%

Interaction between physicians and the pharmaceutical industry: A scoping review for developing a policy brief

Zarei

Ghaffari

Nikoobar

et al. 2023

Front. Public Health

View full text Add to dashboard Cite

show abstract

Who gains and who loses from more information in technology markets? Evidence from the Sunshine Act

Zhang

Branstetter

Conti

et al. 2023

Strategic Management Journal

View full text Add to dashboard Cite

Research SummaryWe consider the context of a technology market where participants (in particular, sellers) differ in reputation, and sellers observed participating in the transactions might suffer a reputation loss. Our theoretical model predicts that low‐reputation idea sellers, thanks to the improvement in information disclosure, are more likely to be involved in technology transactions; at the same time, high‐reputation idea sellers, to protect their reputations, might prefer avoiding any transactions. This shift in seller composition might affect the quantity and quality of collaborations. To test our theory, we assess the effect of the Physician Payment Sunshine Act on physician‐firm collaborations. Overall, our findings indicate that while information disclosure might benefit some market participants, it can have unintended negative consequences for others.Managerial SummaryIn technology markets, more information about market participants generally leads to better outcomes. However, in contexts where sellers suffer a reputation loss if their transactions become known, higher‐reputation sellers may leave the market, affecting the quality of ideas being traded and impacting buyers. On the other hand, lower‐reputation sellers may benefit from increased visibility and share their ideas more frequently. Our research examined these effects in the context of the Physician Payment Sunshine Act, which made physician collaborations with medical device companies visible. The results suggest that the effects of information disclosure are not uniform and that some market participants may benefit while others may suffer losses.

show abstract

Ethical challenges in contemporary psychiatry: an overview and an appraisal of possible strategies and research needs

Galderisi,

Appelbaum,

Gill

et al. 2024

World Psychiatry

View full text Add to dashboard Cite

Psychiatry shares most ethical issues with other branches of medicine, but also faces special challenges. The Code of Ethics of the World Psychiatric Association offers guidance, but many mental health care professionals are unaware of it and the principles it supports. Furthermore, following codes of ethics is not always sufficient to address ethical dilemmas arising from possible clashes among their principles, and from continuing changes in knowledge, culture, attitudes, and socio‐economic context. In this paper, we identify topics that pose difficult ethical challenges in contemporary psychiatry; that may have a significant impact on clinical practice, education and research activities; and that may require revision of the profession's codes of ethics. These include: the relationships between human rights and mental health care, research and training; human rights and mental health legislation; digital psychiatry; early intervention in psychiatry; end‐of‐life decisions by people with mental health conditions; conflicts of interests in clinical practice, training and research; and the role of people with lived experience and family/informal supporters in shaping the agenda of mental health care, policy, research and training. For each topic, we highlight the ethical concerns, suggest strategies to address them, call attention to the risks that these strategies entail, and highlight the gaps to be narrowed by further research. We conclude that, in order to effectively address current ethical challenges in psychiatry, we need to rethink policies, services, training, attitudes, research methods and codes of ethics, with the concurrent input of a range of stakeholders, open minded discussions, new models of care, and an adequate organizational capacity to roll‐out the implementation across routine clinical care contexts, training and research.

show abstract

Physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey

Cited by 4 publications

References 29 publications

Interaction between physicians and the pharmaceutical industry: A scoping review for developing a policy brief

Interaction between physicians and the pharmaceutical industry: A scoping review for developing a policy brief

Who gains and who loses from more information in technology markets? Evidence from the Sunshine Act

Ethical challenges in contemporary psychiatry: an overview and an appraisal of possible strategies and research needs

Contact Info

Product

Resources

About